strong perform acquisit lead growth
maintain buy rate upgrad tp
estim tp base forward
price-to-earnings multipl ep give
upsid potenti also
estim top line revenu growth
estim base follow factor strong
growth revenu earn strong oper margin
expans strong perform across segment new
product launch strateg acquisit
danah deliv strong perform due strong
revenu growth oper margin expans lead
double-digit growth adjust ep free cash flow total
revenu increas
estim adjust ep increas
in-lin estim
deploy capit year includ
acquisit softwar join life
scienc platform ad best class genom consum
capabl softwar part esko enhanc
offer across packag develop product
mn except ep crispidea name corp tickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth corp ch
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
digit led double-digit growth china india
across develop market saw high singl digit
growth us western europ low
total revenu life scienc segment increas
sale busi
broad rang mass spectromet continu grow
y/i basi led strong sale growth high-growth
market particularli china rest asia
led organ growth invest continu
evolut diagnost portfolio
total sale environment appli solut
segment increas
geograph y/i core revenu growth analyt
instrument product line driven increas
demand across major geographi led china north
america western europ
current price-to-earnings multipl
due increas stock price
averag price-to-earnings price-to-earnings
grown past due strong perform
compani expect forward price-to-earnings multipl
recommend buy rate base
perform recent acquisit expect
growth revenu
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date apr ex-dividend date last split factor new per last split date jul inform danah corp ch
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper profit interest incom interest incom incom incom minor net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli corp march
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item danah corp march
oper cash flow continu oper increas due higher
net earn includ higher non-cash charg depreci amort impact
non-cash gain sale market equiti secur lower cash use fund
trade account receiv inventori trade account payabl
net cash use invest activ compar
acquir two busi total consider
financ activ use cash compar decreas
due lower net repay commerci paper borrow compani decreas
commerci paper borrow increas commerci paper borrow cepheid
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu debt- issuanc capit repurchas capit stock- payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end corp march
danah deliv strong revenu growth oper margin expans
lead double-digit adjust ep free cash flow growth
total revenu increas compar
impact foreign currenc translat decreas
revenu acquisit increas revenu quarter
revenu increas five platform deliv better
geograph high growth market grew high singl digit led double-
digit growth china india across develop market saw
high single-digit growth us western europ low singl
cog increas compar
gross profit increas compar
gross margin quarter
compar
compar
sg expens increas compar
 expens increas
compar oper profit increas
compar oper
margin declin bp driven acceler invest spend foreign
currenc impact stronger us dollar tariff relat cost
incom net compar
interest expens compar
interest incom compar
effect tax rate compar
net earn declin compar
ep decreas
compar non-gaap ep increas
compar
total revenu increas compar
sale acquir busi increas y/i basi
due acquisit
geograph high-growth develop market contribut y/i core
sale growth sale growth rate high-growth market grew
high-single-digit rate led strength asia particularli china
high-growth market repres dhr total sale sale
develop market grew mid-singl digit rate driven
north america western europ
cog increas compar
increas cost sale due impact higher y/i sale
volum includ sale recent acquir busi good sold
also increas result tariff tariff estim
modest impact cost good sold
compar
increas
compar
gross margin compar y/i
increas gross profit margin due favor impact higher y/i
sale volum includ sale recent acquir busi increas
leverag certain manufactur cost increment y/i cost save
associ continu product improv taken
gross margin improv partial off-set impact foreign
exchang rate
sg expens increas compar
sg expens sale declin bp
compar declin led increas
leverag dhr gener administr cost base result higher
sale volum continu product improv taken
impact restructur impair relat charg
incur associ dhr strateg decis discontinu
product line diagnost segment
 expens increas compar
 flat total revenu expens
sale remain consist compar y/i increas
spend dhr new product develop initi correspond
increas sale
oper profit increas compar
oper margin compar
oper margin favor impact higher sale volum
increment y/i cost associ variou new product develop
sale market growth invest
incom net compar
interest expens compar
interest expens declin due decreas interest cost result
repay certain outstand borrow
borrow impact foreign currenc exchang rate
effect tax rate compar net
incom increas compar
gaap ep increas compar
non-gaap ep increas compar
compar
compar
danah report segment includ life scienc diagnost dental
total revenu life scienc segment increas
compar total revenu increas
compar
price increas segment contribut revenu growth y/i
basi reflect compon chang core
revenu growth oper profit increas
compar oper margin increas
compar
sale busi broad rang mass spectromet continu
grow y/i basi led strong sale growth high-growth market
particularli china rest asia north america growth led
demand clinic appli pharmaceut end-market
demand servic offer
sale microscopi product continu grow y/i basi
growth demand across major end-market partial driven recent
new product releas geograph demand microscopi product
increas north america high-growth market particularli china
y/i core sale busi flow cytometri particl count
product continu grow across major end-market led
increas sale north america china western europ new product
launch also contribut increas demand market
sale filtrat separ purif technolog grew
y/i basi led growth biopharmaceut microelectron fluid
technolog asset protect end-market geograph core sale
filtrat separ purif technolog led growth
western europ north america high-growth market
total revenu life
increas
compar
sale filtrat
separ
grew y/i basi led
growth
microelectron
fluid technolog
total revenu diagnost segment increas
compar total revenu increas
compar price segment
neg impact sale growth y/i basi
oper profit decreas compar
oper margin increas compar
sale molecular diagnost busi increas y/i basi led
strong growth develop high-growth market molecular
diagnost busi experienc particularli strong growth infecti
diseas product line driven part sever flu season
sale clinic lab busi increas y/i basi due increas
demand high-growth market led china partial off-set lower
sale western europ increas demand clinic lab busi
driven immunoassay product line
sale acut care diagnost busi increas driven continu
strong sale blood ga immunoassay product line across major
geographi led high-growth market
sale patholog diagnost busi increas across major
geographi led north america western europ china demand
new product advanc stain core histolog product line drove
increas core sale patholog diagnost busi
total revenu
increas
compar
sale
major geographi
led north america
western europ
total revenu dental segment increas
compar total revenu flat
price segment neg impact sale growth y/i
basi
oper profit decreas compar
oper margin declin compar
geograph y/i core revenu growth led growth high-growth
market china russia partial off-set declin north
america western europ revenu growth specialti
consum busi consist implant solut orthodont
product led high-growth market china north america
dental equip tradit dental consum core sale declin
due declin north america off-set partial growth
high-growth market china russia
total revenu
increas
compar
dental equip
declin
due declin north
growth high-
russia
lower core sale dental equip tradit dental consum
product line north america partial off-set core revenu growth
specialti consum busi primarili reflect impact inventori
reduct sever distribut partner well impact
realign distributor manufactur dental industri
begun see stabil north america end-market dental
equip tradit dental consum
total sale environment appli solut segment increas
compar total revenu increas
compar price increas
segment contribut sale growth y/i basi
oper profit increas compar
oper margin compar
sale segment water qualiti busi grew high-single-digit
rate y/i core sale analyt instrument product line
increas led continu demand industri municip end-market
geograph y/i core revenu growth analyt instrument
product line driven increas demand across major geographi led
china north america western europ y/i core revenu growth
busi chemic treatment solut product line driven demand
commerci industri mine primari metal end-market
geograph y/i core revenu growth chemic treatment solut
product line driven north america latin america sale
busi ultraviolet water disinfect product line grew y/i basi due
demand municip consum end-market
geograph y/i core revenu growth ultraviolet water disinfect
product line led north america china partial off-set softer
demand western europ
sale segment product identif busi grew mid-
single-digit rate y/i core revenu growth mark
code equip relat consum driven demand across
major end-market major geographi particularli western europ
north america high-growth market
total sale
increas
compar
sale
grew mid-singl
digit rate
demand busi packag color solut decreas slightli y/i
geograph core sale packag color solut decreas north
america high-growth market partial off-set increas demand
sale packag
north america
partial off-set
increas demand
one best-receiv deal health care year isnt hot
biotechnolog compani drug giant megamerg take-over
busi sell product keep medic research pipelin hum
februari ge announc agreement wherebi
acquir busi ge biopharma
cash buy pharmaceut diagnost
busi busi consist mostli slower-grow lower-margin
product group like contrast media molecular imag consum
net tax benefit pay
use combin cash hand debt cash rais two equiti
offer common offer prefer offer
fund deal pay expect ebitda around
forward revenu expect per share ep accret year
one per share accret year five
dhr acquisit busi good move
compani deal masterstrok ge allow ge pare
debt load ge deal bring badly-need cash help
shore busi ceo larri tri turn hamstrung behemoth
crown jewel acquisit put
forefront drug biotech sector hottest field fix seriou health
condit molecular level modifi cell dna grow new
protein suppli machin materi help compani
develop new therapi benefit industri growth
without take stock-kil risk drug trial fail
see meaning opportun har power
busi system provid custom end-to-
end bioprocess solut help enabl breakthrough develop
danah corpor announc februari enter
definit agreement compani acquir
biopharma busi cash purchas price
transact expect complet subject
customari condit includ receipt applic regulatori approv
busi establish stand-alon oper compani within
life scienc segment join compani pall beckman
busi
expect financ all-cash transact proce
equiti offer may includ offer mandatori convert
prefer share remaind avail cash hand proce
issuanc debt and/or new credit facil new debt expect
issu blend interest rate
integr busi within danah busi system provid faster
innov well cost synergi time seen year three
onward term activ compani activ across globe larg
contribut major geograph region expect grow
estim acquisit reduc dilut net ep
accret non-gaap adjust dilut net ep
first full year post acquisit
amort purchas account charg transact expens attribut
acquisit well stand-up cost relat carv busi
dilut impact anticip equiti financ transact
includ non- dilut ep figur
acquisit enhanc already-strong posit
attract grow market equip consum use
produc rang biolog pharmaceut product includ antibodi
vaccin gene therapi
ge biopharma lead provid instrument consum softwar
support research discoveri process develop manufactur
workflow biopharmaceut drug busi compris process
chromatographi hardwar consum cell cultur media single-us
technolog develop instrument consum servic
ge biopharma expect gener annual revenu
revenu consid recur given anticip tax
benefit transact structur net purchas price
repres multipl time expect ebitda
ge biopharma renown provid best-in-class bioprocess
technolog solut deal pivot mileston
demonstr ge execut strategi take thought
deliber action reduc leverag strengthen balanc sheet
share gain much biggest intra-day gain decad
share rose februari ge jump
ahead regular trade new york ge jump close
new york highest level sinc oct share advanc
year best perform standard poor sub-index industri
acquisit bring talent passion team well highli
innov industry-lead product suit life scienc portfolio
provid excel complement current biolog workflow solut
guidanc conclus
expect ep rang non-gaap adjust
ep expect rang
expect adjust ep ep
rang
danah deliv strong perform due strong revenu growth
oper margin expans lead double-digit growth adjust ep
free cash flow
total revenu increas compar
sale acquir busi increas y/i basi
due acquisit ep increas
non-gaap ep increas
total sale environment appli solut segment increas
total revenu life scienc segment increas
total revenu diagnost segment
increas
past sever year combin organ inorgan
initi transform busi higher growth higher
margin higher recur revenu compani strong foothold
portfolio today combin power danah busi system
posit well focus deliv long-term sharehold valu
beyond
expect ep
rang
adjust ep expect
rang
perform due
oper margin
expans lead
double-digit growth
adjust ep free
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas compar due decreas cog
oper margin increas compar
net margin declin compar
y/i revenu growth increas compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corp march
mrqgross mrqoper mrqnet mrqcog mrqr mrqsg sale danah corp march
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset danah corp march
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item danah corp march
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free corp march
current price-to-earnings multipl due increas stock
price averag price-to-earnings price-to-earnings grown past due strong
perform compani expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc price row associ wellington manag compani fmr massachusett servic morgan america northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard price row capit appreci spdr etf mf seri trust i-mf valu parnassu equiti vanguard institut fund-institut price row chip growth fund fidel ishar competit
developmentsdanah announc offer common stock mandatori convert prefer stockfebruari corpor announc commenc concurr offer share common stock share seri mandatori convert prefer stock subject market condit offer expect grant underwrit separ option purchas share common stock share mandatori convert prefer stock danah acquir biopharma busi gener electr life scienc billionfebruari corpor announc enter definit agreement compani acquir biopharma busi ge biopharma cash purchas price given anticip tax benefit transact structur net purchas price repres multipl time expect ebitda ge biopharma danah announc spin dental busi independ publicli trade companyjun corpor announc intent spin dental segment independ publicly-trad compani dentalco transact intend tax-fre sharehold expect complet second half believ dental busi effect stand-alone compani greater focu around organ inorgan invest opportun corp march
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
roa roi roe ttm
basi stood
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corp march
consensu view analyst trend stock
rate expect
compar
 growth
rate
dhr forward price-to-earnings
higher
annual usdgrowth high day day day estim avgfive-year growth forecast comparisondhrindustri avg avgprice/earn yield corp march
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr corp march
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price volatil period show upward trend sinc februari
announc acquisit
stock gave return period averag volum share trade
stock price volatil past one year surg march
stock gave return past one year rang stock
stock price shown upward trend past year due strong growth busi
stock given total return last year
danah deliv strong perform year growth revenu
increas ep non- ep increas recommend
buy rate tp base recent acquisit strong perform
year
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
